|Elimination half-life||4 hours|
TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.  It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|